Findings from a large cohort study need urgent verification in populations outside Europe, say experts.
Treatment with an integrase inhibitor was associated with an increased risk of heart attack or stroke during the first two years of exposure to the drug class when compared to treatment with other antiretroviral drugs, a large study of people receiving treatment since 2012 has found.
The study, which assembled data on more than 29,000 people with HIV receiving treatment in Europe, Argentina and Australia, showed that the risk of a cardiovascular event – a heart attack, a stroke or a clinical intervention to relieve serious heart disease such as stenting or angioplasty – almost doubled in the first six months after starting a regimen containing an integrase inhibitor when compared to other regimens, after controlling for underlying cardiovascular risk factors such as high lipid levels and high blood pressure.
However, the increased risk was no longer evident after people had received more than two years of treatment with an integrase inhibitor.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
TheBodyPro: Can long-acting regimens solve virologic failure in heavily treatment-experienced people with HIV?
-
[Press release] TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 in HIV maintenance therapy study
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.